Business Context and Reporting Period
This Form 8-K Current Report was filed by Tenaya Therapeutics, Inc. on June 29, 2026. The filing discloses the appointment of a new Chief Financial Officer (CFO) and the transition of the Principal Financial Officer and Principal Accounting Officer roles.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on executive compensation and personnel changes.
Material Changes
- Executive Appointment: Eric Hyllengren, M.B.A., was appointed as Chief Financial Officer, effective July 13, 2026. He will also serve as the Principal Financial Officer and Principal Accounting Officer.
- Role Transitions: Faraz Ali, President and CEO, ceased serving as interim Principal Financial Officer. Tomohiro Higa, Senior Vice President of Finance, ceased serving as acting interim Principal Accounting Officer.
- Compensation Package:
- Annual Base Salary: $490,000.
- Target Annual Bonus: 40% of base salary.
- Equity Grant: Option to purchase 1,650,000 shares of common stock under the 2024 Inducement Equity Incentive Plan.
- Vesting Schedule: 25% on the first anniversary of the grant date, with the remainder vesting monthly (1/48th) thereafter.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or management commentary regarding business operations. It notes that Mr. Hyllengren is eligible to participate in the Company's Executive Change in Control Severance Plan, with details referenced in the 2026 Proxy Statement. No specific risks or contingencies related to financial performance are disclosed in this report.
Investor Verification Checklist
- Verify the commencement date of July 13, 2026, for the new CFO.
- Review the attached Offer Letter (Exhibit 10.1) for full terms of the equity grant and severance plan eligibility.
- Confirm the vesting schedule details for the 1,650,000 stock options.
- Check the 2026 Proxy Statement for specific details on the Executive Change in Control Severance Plan.